inCerebro

The company's proprietary MIND platform is specifically designed to identify novel small molecule therapeutics for difficult targets like GPCRs and previously intractable protein targets. The platform combines key technologies such as QM/MM docking, Water pharmacophore, and binding free energy calculations, surpassing the currently standardized technology to create cost-saving and time-efficient solutions for early drug discovery. Our team includes world-renowned scientists and industry leaders in physics-based computational platforms and machine learning technologies. InCerebro also offers its technology both as drug discovery service and as MIND platform technology to accelerate hit identification and lead optimization. We welcome discussions with partners who are interested in investing, co-developing our pipelines, or integrating our physics and AI-based drug discovery platform.